摘要
目的探讨血清β2-MG检测在恶性骨肿瘤中的临床应用价值。方法采用放射免疫测定对38例恶性肿瘤、12例良性骨肿瘤及16例正常健康成人的血清β2-微球蛋白(β2-MG)水平进行了检测,并进行对比分析。结果三组检测样本血清β2-MG水平分别为(4.17±0.85)mg/L、(1.82±0.37)mg/L和(1.73±0.40)mg/L,表明恶性骨肿瘤患者β2-MG水平明显高于良性骨肿瘤与正常人,有显著性差异(P<0.01);同时还发现β2-MG水平与恶性骨肿瘤的临床分期、治疗反应有明显相关性。结论血清β2-MG测定可作为恶性骨肿瘤的辅助诊断及评估治疗、病情的血清学指标之一。
Objective To explore the value of Serum β2-MG in diagnosing malignant bone tumor.Methods Serum β2-MG of 38 patients with malignant bone tumor,12 patients with benign bone tumors and 16 normal healthy adults was examined by radioimmunoassay,and comparative analysis was conducted.Results Three groups of test samples of serum β2-MG levels were（4.17±0.85） mg/L,（1.82±0.37） mg/L and（1.73±0.40） mg/L,which showed that patients with malignant bone tumor of β2-MG levels were significantly higher than that of benign bone tumors and normal adults,and the difference was statistically significant（P〈0.01）.It was also found that the level of β2-MG and malignant bone tumors,clinical staging,and response to treatment had a significant correlation.Conclusion Determination of serum β2-MG can be an aid of diagnosis of malignant bone tumors and assessment of treatment,and one of the serological markers of the condition.
出处
《实用临床医药杂志》
CAS
2012年第15期77-78,81,共3页
Journal of Clinical Medicine in Practice
